<DOC>
	<DOCNO>NCT02447328</DOCNO>
	<brief_summary>This single-arm study aim assess safety tolerability profile Fulvestrant ( Faslodex® ) 2nd line later therapy postmenopausal woman locally advance metastatic breast cancer . The primary objective evaluate adverse event Fulvestrant ( Faslodex® ) 6 month</brief_summary>
	<brief_title>A Single Arm , Tolerability Safety Phase IV Study Fulvestrant ( Faslodex® ) 2nd Line Later Therapy Postmenopausal Women With Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>This study Phase 4 , single-arm , safety tolerability study fulvestrant ( Faslodex® ) 2nd line therapy postmenopausal woman locally advance metastatic breast cancer . All enrol patient study inject fulvestrant ( Faslodex® ) . This study perform 3 year approximately 100 patient ( actual target 80 treated patient ) enrol 10 investigational site . After obtain write informed consent patient , information demographic medical history collect laboratory test perform . Patients meet inclusion/exclusion criterion inject fulvestrant ( Faslodex® ) 500mg/month 6 month additional 500mg dose give 14 day initial dose injection . The information adverse event collect 1st dose IP injection . In case evaluation tumor response might perform regular clinical practice , data also collect well . The quality life also measure .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Post menopausal status woman Outpatient inpatient locally advance metastatic breast cancer fail prior antiestrogen therapy . Estrogen receptor positive Radiographic progression disease prior therapy Patients agree participate study sign inform consent Patients treat fulvestrant Patients treat antitumor agent Pregnancy lactate woman History hypersensitivity include ingredient ( eg . Castor oil ) Patients consider fit study investigator Patients severe dysfunction liver kidney</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>